Human medicines European public assessment report (EPAR): Praluent, alirocumab, Date of authorisation: 23/09/2015, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Praluent, alirocumab, Date of authorisation: 23/09/2015, Revision: 21, Status: Authorised

Metadata
Provider: 
European Medicines AgencyEuropean Medicines Agency
URL: 
https://www.ema.europa.eu/en/medicines/human/EPAR/praluenthttps://www.ema.europa.eu/en/medicines/human/EPAR/praluent
Retrieved on: 
Friday, January 5, 2024
Information
Tags: 
Patient, Common, Medical Subject Headings, Marketing, LDL, Cholesterol, Artery, Agency, INN, Risk, Hypercholesterolemia, IIA, ATC, Moyamoya disease, Comparable, Pain, Blood, International, Diet, Coronary artery disease, Disease, Ageing, Nose, Language, Heart, Stroke, Abdomen, Red, Splenic infarction, Goal, European Medicines Agency, Thigh, Select, Cell, Chest pain, Safety, Fats, Anatomy, PCSK9, Ezetimibe, Primary, Throat, Skin, Medical device
Geotags: 
EU
Summary
Key Points: 


Human medicines European public assessment report (EPAR): Praluent, alirocumab, Date of authorisation: 23/09/2015, Revision: 21, Status: Authorised

Copyright: 
2024 European Medicines Agency. All Rights Reserved.